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Objective: We hypothesized that diabetes-related distress would vary by type of diabetes and medication
regimen [Type 1 diabetes (T1DM), Type 2 diabetes with insulin use (T2DM-i), Type 2 diabetes without
insulin use (T2DM)]. Thus, the aim of this study was to identify groups with elevated diabetes-related
distress.
Methods: We administered the 17-item Diabetes-related Distress Scale (DDS-17) to 585 patients. We
collected demographics, medications, and lab results from patient records.
Results: Patients were categorized by type of diabetes and medication: T1DM (n = 149); T2DM-i (n = 333);
and T2DM (n = 103). ANOVA revealed signiﬁcant differences in sample characteristics. ANCOVA were
conducted on all four DDS-17 domains [Emotional Burden (EB); Physician-related Distress (PD);
Regimen-related Distress (RD); and Interpersonal Distress (ID)]; covariates included in the models were
sex, age, duration of diabetes, BMI, and HbA1c. EB was signiﬁcantly lower in T1DM than T2DM-i, p < 0.05.
In addition, RD was signiﬁcantly lower in T1DM than either T2DM-i, p < 0.05 and T2DM, p < 0.05.
Conclusions: EB and RD are higher for those with type 2 diabetes. Thus, interventions to reduce EB and RD
need to be considered for patients with type 2 diabetes.
Implications: DDS-17 is useful in identifying diabetes-related distress in patients with diabetes. Efforts
need to be made to reduce EB and RD.
Published by Elsevier B.V.
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Managing diabetes is not easy. Polonsky and associates describe
diabetes as a “complex, demanding, and often confusing set of selfcare directives” in which “patients may become frustrated, angry,
overwhelmed, and/or discouraged” (p. 626) [1]. Accordingly, the
American Diabetes Association (ADA) position statement recommends psychosocial assessment as an integrated part of routine
care for people with diabetes (Young-Hyman, 2016) [2].
The concept of diabetes-related distress, which encompasses
patients’ concerns about self-care, support, emotional burden, and
quality of healthcare, is a common challenge for people with

Abbreviations: ADA, American Diabetes Association; ANOVA, analysis of
variance; DoD, Department of Defense; DCOE, Diabetes Center of Excellence;
DDS-17, Diabetes-related Distress Scale; EB, emotional burden; ID, interpersonal
distress; PD, physician-related distress; RD, regimen-related distress; T1DM, type 1
diabetes; T2DM-i, type 2 diabetes with insulin use; T2DM, type 2 diabetes without
insulin use.
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diabetes [1,3]. While depression is prevalent in people with
diabetes, diabetes-related distress has been found to be even more
common, with a prevalence of 18–35% [4,5]. Diabetes-related
distress is noted to be a separate clinical entity, whereby about 70%
of patients with identiﬁed diabetes-related distress were not
clinically depressed [4,6]. Diabetes-related distress can be assessed
using the 17-item Diabetes-related Distress Scale (DDS-17), which
measures diabetes-related distress in four distinct domains: 1)
emotional burden (EB); 2) physician-related distress (PD); 3)
regimen-related distress (RD); and 4) interpersonal distress (ID)
[1–3]. These domains are further described in Table 1.
Elevated diabetes-related distress is related to poorer selfmanagement, worse medication adherence, and lower quality of
life [7,8]. Moreover, greater HbA1c values correlate with higher
diabetes-related distress [5,8]; conversely, lower diabetes-related
distress levels are associated with patient self-efﬁcacy and
physician support [9]. In addition, higher DDS-17 scores were
associated with women, younger patients, and those with higher
BMI [9]. For patients with T1DM, diabetes-related distress has been
experienced somewhat differently than for patients with T2DM
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Table 1
The 17-item Diabetes-related Distress Scale (DDS-17).
Emotional Burden (EB)
1. Feeling that diabetes is taking up too much of my mental and physical energy every day.
2. Feeling angry, scared, and/or depressed when I think about living with diabetes.
3. Feeling that diabetes controls my life.
4. Feeling that I will end up with serious long-term complications, no matter what I do.
5. Feeling overwhelmed by the demands of living with diabetes.
Physician-related Distress (PD)
1. Feeling that my doctor doesn’t know enough about diabetes and diabetes care.
2. Feeling that my doctor doesn’t give me clear enough directions on how to manage my diabetes.
3. Feeling that my doctor doesn’t take my concerns seriously enough.
4. Feeling that I don’t have a doctor who I can see regularly enough about my diabetes.
Regimen-related Distress (RD)
1. Feeling that I am not testing my blood sugars frequently enough.
2. Feeling that I am often failing with my diabetes.
3. Not feeling conﬁdent in my day-to-day ability to manage diabetes.
4. Feeling that I am not sticking closely enough to a good meal plan.
5. Not feeling motivated to keep up my diabetes self-management.
Interpersonal Distress (ID)
1. Feeling that friends or family are not supportive enough of self-care efforts (e.g. planning activities that conﬂict with my schedule, encouraging me to eat the “wrong”
foods).
2. Feeling that friends or family don’t appreciate how difﬁcult living with diabetes can be.
3. Feeling that friends or family don’t give me the emotional support that I would like.
Responses are on a 6 point continuum from 1 = Not a problem; 2 = A slight problem; 3 = A moderate problem; 4 = Somewhat serious problem; 5 = A serious problem; 6 = A very
serious problem.

[10]. EB originates predominantly from a sense of powerlessness,
reﬂecting ongoing frustrations with managing glucose when much
of the variation is outside of their control [10]. RD also comes from
concerns about not monitoring blood glucose enough, fears that
eating constraints are controlling their life, and a more pronounced
fear of hypoglycemia [10]. To a lesser extent, patients with T1DM
have interpersonal and physician-related distress.
Despite knowing the relationship of diabetes-related distress to
diabetes-related health outcomes, the relationship to type of
diabetes and medication regimen has not been evaluated.
This study sought to explore these factors as they relate to high
diabetes-related distress measured by DDS-17 in a diabetes clinic
setting. We hypothesized that DDS-17 would signiﬁcantly vary by
type of diabetes and medication regimen [Type 1 diabetes (T1DM),
Type 2 diabetes with insulin use (T2DM-i), Type 2 diabetes without
insulin use (T2DM)]. The goal of our study was to identify groups

with elevated diabetes-related distress, which would enable a
targeted intervention to decrease diabetes-related distress in the
speciﬁc domain.
1. Research design and methods
Wilford Hall Ambulatory Surgical Center Institutional Review
Board approval was obtained for this retrospective data analysis.
Data were collected at the Diabetes Center of Excellence (DCOE)
through chart reviews of clinical visits from June 2015 through
August 2016. The DCOE is an Air Force diabetes specialty clinic
treating challenging cases of diabetes including patients with type
1 diabetes (T1DM) and patients with complex diabetes. Our patient
population consists of all branches of active duty military, retired,
and family members. The DCOE began administering the 17-item
Diabetes-related Distress Scale (DDS-17) in June 2015 as standard

Fig. 1. “DDS-17 Dashboard in the NoteWriter”.
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care (Table 1). Responses were on a 6 point continuum from 1 = Not
a problem; 2 = A slight problem; 3 = A moderate problem;
4 = Somewhat serious problem; 5 = A serious problem; 6 = A very
serious problem. DDS-17 domains were calculated as a sum of the
total and divided by the number of items in each domain: EB (5
items); PD (4 items); RD (5 items); and ID (3 items). It should be
noted that Fenwick et al. [11] suggest that total DDS-17 score
should be avoided; thus discussion of the four individual domains
will be presented.
Inclusion criteria were adult patients (19 and older) with
diabetes receiving their diabetes care at the DCOE. Data were
stored on military computers that were password and ﬁrewall
protected. As part of the regular patient visit, all patients
completed the DDS-17 and responses were recorded by licensed
vocational nurses. All patients completed a DDS-17 as part of the
clinical visit (N = 585).
After input, the NoteWriter, an Excel-based clinical note writing
platform, calculated scores for total DDS and each subscale. Fig. 1
shows the NoteWriter, DDS-17 total and subscale scores with
associated level of distress designated by a color-coded radial
button on the dashboard: green indicated <2.0 = little or no
diabetes-related distress; yellow indicated 2.0–2.9 or moderate
diabetes-related distress; or red !3.0 signaled high diabetesrelated distress, which are consistent with cut points established
by Fisher et al. [12]. The area(s) designated as yellow or red were
further explored by the provider to determine the source of the
diabetes-related distress and collaborate with the patient to
determine strategies to reduce the associated distress.
In addition to the DDS-17, data included patient demographics
(gender, age, ethnicity/race, rank, military status) and lab results
(comprehensive metabolic panel including HbA1c).
Analyses were conducted using SPSS version 22. Univariate
analyses were conducted to characterize the sample. Type of
diabetes and medication regimen were used to transform data into
three distinct groups (T1DM, T2DM-i, and T2DM). One-way
analysis of variance (ANOVA) were conducted to assess differences
in means between and among groups on sample characteristics.
This was followed by Analysis of Covariance (ANCOVA) to control

for signiﬁcantly different sample characteristics when examining
the four domains of DDS-17 among the three groups.
2. Results
A total of 610 DCOE patients completed a baseline DDS-17 from
June 2015 through August 2016. However, 25 patients were
categorized as “other” type of diabetes, which left 585 patients that
could be categorized.
One-way ANOVA was conducted to detect signiﬁcant differences among and between groups on demographic and clinical
markers (Table 2). There were slightly more men than women
represented in the data with signiﬁcant variation between the
T1DM group and the T2DM-i group according to sex. Patients with
T1DM were signiﬁcantly younger (46.0 years) than the other
groups. As expected, T1DM patients were signiﬁcantly younger at
diagnosis (26.5 years) compared to the Type 2 diabetes groups.
Duration of diabetes was signiﬁcantly higher in T1DM (20.1 years)
followed by T2DM-i (16.9 years) and T2DM (9.1 years). Overall,
43.3% of the sample were White; 21.6% were African American; and
27.5% Hispanic/Latino. Those in the T1DM category were mostly
White (63.5%); this was signiﬁcantly higher when compared to
each of the Type 2 diabetes groups. There was no signiﬁcant
difference in African Americans among the three groups; however,
Hispanics were signiﬁcantly lower in the T1DM group compared to
each of the Type 2 diabetes groups.
Military rank included both active duty and retired members
and was evenly distributed within the T1DM category, but in the
T2DM-i and T2DM groups, senior enlisted were signiﬁcantly higher
and represented about 40% of the sample. Family members
accounted for about 66% of the T1DM group and about 40% of the
Type 2 DM groups.
Clinical measures included BMI and HbA1c. Both were lowest in
the T1DM group, followed by the T2DM group and highest in
T2DM-i patients; this was signiﬁcantly different between the
T1DM group and each of the Type 2 diabetes groups.
The four DDS-17 subscales were subjected to analysis of
covariance (ANCOVA) to examine differences in means between

Table 2
Sample Characteristics by Type of Diabetes and Medication Regimen Compared across Groups.
T1DM

Sex
Female
Male
Mean Age
Age at Diagnosis
Duration of Diabetes
Ethnicity/Race
White
African American
Hispanic/Latino
Military Rank
Junior Enlisted
Senior Enlisted
Ofﬁcer
Military Status
Active Duty
Retired
Family Member
BMI
Current HbA1c

T2DMi

T2DM

n
149

%
25.5%

n
333

%
56.9%

n
103

%
17.6%

P value

82
67
46.0c
26.5a,b
20.1c

55.0%a
45.0%a
–
–
–

141
192
59.9c
43.2a
16.9c

42.3%a
57.7%a
–
–
–

43
60
53.3c
45.6b
9.1c

41.7%
58.3%
–
–
–

<0.05

94
30
16

63.5%a,b
20.3%
10.8%ab

127
73
106

38.4%a
22.1%
32.0%a

31
23
38

30.1%b
22.3%
36.9%b

<0.05
NS
<0.05

15
17
17

30.6%a
34.7%a,b
34.7%

76
89
26

39.8%a
46.6%a
13.6%

22
27
8

38.6%
47.4%b
14.0%

<0.05
<0.05
NS

14
36
96
28.48c
8.00%

9.6%a
24.7%a,b
65.8%a,b
–
–

10
182
137
33.86c
8.38%

3.0%a,b
55.3%a
41.6%a
–
–

10
48
45
31.15c
8.30%

9.7%b
46.6%b
43.7%b
–
–

<0.05
<0.05
<0.05
<0.05
NS

NS = No Signiﬁcance.
T1DM = Type 1 diabetes; T2DM-i = Type 2 diabetes on insulin therapy; T2DM = Type 2 diabetes not on insulin therapy.
a
Signiﬁcant difference between these 2 variables (<0.05).
b
Signiﬁcant difference between these 2 variables (<0.05).
c
Signiﬁcant difference among all 3 variables (<0.05).

<0.05
<0.05
<0.05
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and among groups when controlling for covariates (age, sex,
duration of diabetes, BMI, and HbA1c) and applying a Bonferroni
correction to adjust for multiple comparisons (Table 3). Levene’s
test was conducted for all models, normality checks were carried
out and assumptions were met.
After controlling for covariates, those with T1DM had signiﬁcantly lower EB than those with T2DM-i, F(7, 547) = 11.715,
p < 0.001, partial n2 = 0.026. The covariates of younger age
(b = "0.018; SE = 0.004, p < 0.001) and higher HbA1c (b = 0.171;
SE = 0.03, p < 0.001) were associated with higher EB. This model
explains 11.9% of the variance in EB.
After controlling for covariates, the overall model for PD was not
signiﬁcant for differences among or between groups, F(2,
547) = 1.730, p = 0.178, partial n2 = 0.006. However, younger age
(b = "0.006; SE = 0.003, p = 0.03) and higher HbA1c (b = 0.056;
SE = 0.02, p = 0.002) were associated with higher PD. This model
explains 2.8% of the variance in PD.
After adjusting for covariates, those with T1DM had signiﬁcantly lower RD than T2DM-i and T2DM, F(2, 547) = 5.291,
p = 0.005, partial n2 = 0.019. Signiﬁcant differences were found
between T1DM and T2DM-i groups (p = 0.005) and T1DM and
T2DM groups (p = 0.033). Covariates of younger age (b = "0.016;
SE = 0.004, p < 0.001), female sex (b = 0.237; SE = 0.08, p = 0.005),
higher BMI (b = 0.014; SE = 0.01, p = 0.02), and higher HbA1c
(b = 0.184; SE = 0.03, p < 0.001) were associated with higher RD.
This model explains 15.6% of variance in RD.

Table 3
ANCOVA on DDS-17 Domains by Type of Diabetes and Medication Regimen.
T1DM
n
149

%
25.5%

Emotional Burden (EB)
96
64.4%
Low
30
20.1%
Moderate
High
23
15.4%
1.868(0.99)
M(SD)
Adjusted M(SE) 1.694(0.10)a
(1.50; 1.89)
95% CI
Physician-related Distress (PD)
Low
140
94.0%
6
4.0%
Moderate
3
2.0%
High
1.171(0.51)
M(SD)
Adjusted M(SE) 1.149(0.07)
1.02, 1.28
95% CI
Regimen-related Distress (RD)
98
65.8%
Low
35
23.5%
Moderate
High
16
10.7%
1.859(0.96)
M(SD)
Adjusted M(SE) 1.786(0.09)a,b
1.60, 1.97
95% CI
Interpersonal Distress (ID)
Low
123
82.6%
14
9.4%
Moderate
High
12
8.1%
1.1415(0.85)
M(SD)
Adjusted M(SE) 1.391(0.08)
95% CI
1.23, 1.56

T2DM-i

T2DM

n
333

n
103

%
56.9%

ANCOVA
%
17.6%

182
54.7%
84
25.2%
67
20.1%
2.108(1.15)
2.166(0.06)a
(2.05; 2.29)

62
60.2%
29
28.2%
12
11.7%
1.874(0.93)
1.951(0.11)
(1.73; 2.17)

301
90.7%
15
4.5%
16
4.8%
1.261(0.76)
1.265(0.04)
1.19, 1.35

90
87.4%
6
5.8%
7
6.8%
1.320(0.69)
1.341(0.08)
1.19, 1.49

177
53.2%
91
27.3%
65
19.5%
2.137(1.06)
2.159(0.06)a
2.05, 2.27

59
57.3%
25
24.3%
19
18.4%
2.113(1.04)
2.156(0.11)b
1.95, 2.37

259
77.8%
46
13.8%
28
8.4%
1.500(0.89)
1.496(0.05)
1.40, 1.60

89
86.4%
8
7.8%
6
5.8%
1.372(0.80)
1.427(0.10)
1.24, 1.61

p value

<0.05

NS

<0.05

NS

T1DM = Type 1 diabetes; T2DM-i = Type 2 diabetes on insulin therapy; T2DM = Type
2 diabetes not on insulin therapy.
Cut points for DDS-17 domains were established by Fisher et al. (2012) and include
<2.0 = little or no distress; 2.0–2.9 = moderate diabetes-related distress; !3 = high
diabetes-related distress.
Models were adjusted for age, sex, duration of diabetes, BMI, and HbA1c.
NS = No Signiﬁcance.
a
Signiﬁcant difference between these 2 variables (<0.05).
b
Signiﬁcant difference between these 2 variables (<0.05).
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ID was not signiﬁcantly different among groups, F(2,
547) = 0.0573, p = 0.56, partial n2 = 0.002. However, covariates of
female sex (b = 0.221; SE = 0.37, p = 0.003) and higher HbA1c
(b = 0.084; SE = 0.02, p < 0.001) were signiﬁcantly associated with
higher ID. This model explains 4.0% of variance in ID.
3. Discussion
Our results demonstrate that EB and RD were experienced
differently in our patients by type of diabetes and medication
regimen; however, PD and ID were not signiﬁcantly different
among the three groups. Patients in either T2DM-i or T2DM
reported signiﬁcantly higher RD compared with T1DM. Only
T2DM-i patients were signiﬁcantly more likely to experience EB
than patients with T1DM. Identifying EB and RD as the predominant sources of diabetes-related distress enables targeted interventions and modiﬁcations in our patient-centered encounters to
reduce these sources of distress.
Self-care requirements, perception of higher disease severity,
physical discomfort of injections, fear of hypoglycemia, and
anxiety related to other complications are cited as unique sources
of EB for patients taking insulin [13,14]. Even the thought of insulin
has been associated with high EB for those who do not yet require
insulin. Many patients view insulin as a sign of failure in self-care
and a forecast of reduced ﬂexibility in life [15,16]. The negative
appraisal of insulin and the resulting high EB are important
insights for the provider. How insulin therapy is presented must be
considered when designing diabetes education and engaging in
shared decision-making towards meaningful clinical goals.
Those with high EB, whether or not they were already on
insulin, were found to have negative appraisals of insulin therapy
[17]. For the T2DM group not on insulin, EB was the second leading
cause of diabetes-related distress after RD. Since the DCOE is a
diabetes specialty clinic and cares for patients with more complex
diabetes, our patients with T2DM may experience increased
anxiety about the possibility of initiating insulin therapy if their
diabetes cannot be effectively managed on non-insulin medications. People with diabetes are often anxious about initiating
insulin therapy [17,18] and providers may help alleviate reluctance
by discussing and addressing beliefs about insulin therapy.
Furthermore, there is evidence that elevated EB may be associated
with a sense of powerlessness with managing diabetes; many
factors related to optimal blood sugar management are not within
the control of the patient [10].
Insulin therapy is one factor in EB, but EB is a more
comprehensive construct.
In totality, other forms of diabetes-related distress feed into a
patient’s EB. For example, a survey study among ethnically diverse
patients with T2DM found that culturally competent communication and trust in their physicians, a factor in PD, were associated
with lower EB [18,19]. Additionally, the perception of low social
support, a factor in ID, was associated with higher EB [20]. Our
population reported relatively low levels of PD and ID. Therefore,
our results would suggest that high EB in our population may be
attributed to the insulin requirement. However, to avoid over
simpliﬁcation, future studies should explore other factors that may
be related to elevated EB.
An interesting ﬁnding in this study is that people with T2DM-i
and T2DM were signiﬁcantly more likely to have RD than people
with T1DM. People with T1DM require insulin upon diagnosis, but
many people with type 2 diabetes manage diabetes with lifestyle
adjustments and/or non-insulin regimens for a period of time [21],
which may make adding insulin therapy more complex by
comparison. Patients with type 2 diabetes may additionally
experience a sense of guilt that they are responsible for the
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disease progression, which may be compounded by a sense of
failure if they require insulin [10,22,23].
Furthermore, people with type 2 diabetes often have cooccurring conditions (ie hypertension, dyslipidemia, cardiovascular disease), which require additional medications [21].
Logically, patients are more adherent to simple medication
regimens compared to complex ones; thus, a reasonable
conclusion is that simpler medication regimens would induce
less RD. However, this over simpliﬁes RD; medication dosing is
only one factor than can contribute to RD. All patients with
diabetes share challenges with multifaceted management regimens, which include blood sugar monitoring, timing of medication with meals, and concerns about extremes in blood sugar as a
consequence of intentional or unintentional non-adherence to
any aspect of the regimen.
Overall, in our patient population, PD contributed the least to
diabetes-related distress, as about 90.7% had low PD. We attribute
this ﬁnding to several causes. Primarily, we conducted the study at
the DCOE, a specialty center where patients receive care from
endocrinologists or from providers who are closely supervised by
endocrinologists. A patient is less likely to have a concern about a
provider’s diabetes knowledge in our center as compared to a
primary care clinic.
Additionally, the DCOE embraces a multidisciplinary approach
to each patient encounter such that several individuals interact
with the patient [25]. Before the visit, medical assistants review
the patient record to identify any issues or upcoming deadlines to
meet diabetes standard of care. During the visit, they also perform
a structured patient intake, medication reconciliation, and
perform foot examinations when due. These actions enable
providers to be more focused on patient concerns and treatment
plans during their portion of the encounter. Certiﬁed diabetes
educators are available after the provider visit to reinforce the
plan and perform additional teaching regarding how to use new
equipment (e.g., insulin pens, continuous glucose monitors,
insulin pumps, etc.).
A patient-centered approach is central to the DCOE philosophy.
The concepts of motivational interviewing and shared-decision
making are discussed, reviewed, and taught by staff on a regular
basis. It is, therefore, very unusual for a patient to voice a complaint
that his or her concerns are unheard or not taken seriously. Finally,
the DCOE support staff members make themselves available to
patients between provider visits by inviting phone calls to the
clinic, communication via the secure messaging system, or
additional Certiﬁed Diabetes Educator encounters as needed to
address issues. Concerns that cannot be addressed by support staff
are elevated to providers.
A signiﬁcant negative correlation between social support
satisfaction and ID has been described with number of supports
and support satisfaction signiﬁcantly moderating the relationship
between diabetes burden and ID [26]. Lower ID was seen with
higher levels of social support, including an increase in number of
individuals available to provide support [26]. Furthermore, social
support was associated with improved clinical outcomes and
improved adaptation of beneﬁcial lifestyle activities [26,27]. ID in
our population was low among all groups and without statistical
difference among the groups. This may be attributable to the fact
that military members, retirees, and their families represent a
unique subset of the population with access to established family
support programs and resource centers created by the military to
help improve support structures [28]. Lower divorce rates
compared to the civilian sector may be another area that explains
lower ID through increased social support, as cohabitation/marital
status has been shown to have better diabetes-related outcomes
and lower diabetes-related distress with increased social support
as the explanatory factor [29,30].

4. Limitations
Several limitations must be noted due to our distinctive
population and generalizability must be done with caution.
Application of the DDS-17 in a different population yielded
opposite results with higher PD and ID in those with T2DM,
underscoring the heterogeneity in the spectrum of patient distress
[8]. The DCOE is an Air Force diabetes specialty clinic, which
exclusively treats Department of Defense (DoD) beneﬁciaries [25].
Thus, access to healthcare differs from a civilian population.
Notably, there is no cost for healthcare including visits, medication,
and blood sugar monitoring supplies. This may inﬂuence diabetesrelated distress in a number of ways. One could argue that this
beneﬁt would reduce DDS-17 across all domains; however, along
with essentially free healthcare comes limited choice in providers
and reduced options, as some medications are not included on the
formulary. In addition, some of our patients travel long distances to
receive care at the DCOE, which could be an additional stressor.
Future studies may want to examine the role of disease severity
in diabetes-related distress including co-morbidities and diabetesrelated complications. In addition, examining the contribution of
various indicators of disease severity including length of diagnosis,
HbA1c, number and type of medication(s), and complications
associated with diabetes.
5. Practice implications
Providers beneﬁt from an awareness of the differences in
diabetes-related distress experienced by patients according to the
type of diabetes and their medication regimen. Since insulin
therapy is associated with higher RD and EB, intentional efforts
must be made to assist patients in understanding that diabetes is a
progressive condition. Insulin therapy may become necessary over
time even if the person with diabetes has been able to manage
diabetes well on non-insulin therapies.
Furthermore, providers may inadvertently be contributing to
patient distress when they suggest the patient should be able to
“control” diabetes [24]. Instead, empowering patients to learn
skills and strategies to better manage diabetes is necessary.
Certiﬁed diabetes educators can be invaluable in assessing current
skills, improving problem solving, and teaching techniques to
reduce pain of injections or ﬁnger sticks.
Employing an interdisciplinary approach to caring for patients
experiencing elevated diabetes-related distress is optimal. This
may include a PharmD who can reconcile medications and suggest
alternative combo medications. It may also include a mental
healthcare professional who can assist with ID, use therapeutic
approaches designed to lower anxiety or reduce intrusive
thoughts.
6. Conclusion
Diabetes-related distress is an important psychosocial aspect of
care for people with diabetes. Assessing diabetes-related distress
on a regular basis is consistent with standards of diabetes care [21].
Understanding who may be experiencing diabetes-related distress
and where the source of the distress is located assists providers in
tailoring interventions to reduce diabetes-related distress; thus,
enabling patients to better engage in self-management and reach
their treatment goals.
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